Emerging novel approaches for ALL: inotuzumab ozogamicin

The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies are showing promising results. Here, Wendy St... Author: VJHemOnc Added: 07/16/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts